411 related articles for article (PubMed ID: 23415776)
1. Evaluation of moxifloxacin 0.5% in treatment of nonperforated bacterial corneal ulcers: a randomized controlled trial.
Sharma N; Goel M; Bansal S; Agarwal P; Titiyal JS; Upadhyaya AD; Vajpayee RB
Ophthalmology; 2013 Jun; 120(6):1173-8. PubMed ID: 23415776
[TBL] [Abstract][Full Text] [Related]
2. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.
Shah VM; Tandon R; Satpathy G; Nayak N; Chawla B; Agarwal T; Sharma N; Titiyal JS; Vajpayee RB
Cornea; 2010 Jul; 29(7):751-7. PubMed ID: 20489580
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.
Constantinou M; Daniell M; Snibson GR; Vu HT; Taylor HR
Ophthalmology; 2007 Sep; 114(9):1622-9. PubMed ID: 17822972
[TBL] [Abstract][Full Text] [Related]
4. Gatifloxacin 0.3% Versus Fortified Tobramycin-Cefazolin in Treating Nonperforated Bacterial Corneal Ulcers: Randomized, Controlled Trial.
Sharma N; Arora T; Jain V; Agarwal T; Jain R; Jain V; Yadav CP; Titiyal J; Satpathy G
Cornea; 2016 Jan; 35(1):56-61. PubMed ID: 26509763
[TBL] [Abstract][Full Text] [Related]
5. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis.
Panda A; Ahuja R; Sastry SS
Eye (Lond); 1999 Dec; 13 ( Pt 6)():744-7. PubMed ID: 10707137
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group.
O'Brien TP; Maguire MG; Fink NE; Alfonso E; McDonnell P
Arch Ophthalmol; 1995 Oct; 113(10):1257-65. PubMed ID: 7575256
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group.
Hyndiuk RA; Eiferman RA; Caldwell DR; Rosenwasser GO; Santos CI; Katz HR; Badrinath SS; Reddy MK; Adenis JP; Klauss V
Ophthalmology; 1996 Nov; 103(11):1854-62; discussion 1862-3. PubMed ID: 8942881
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin for bacterial keratitis.
Rosenberg J; Eisen L; Kim J
Ophthalmology; 2008 Jun; 115(6):1103; author reply 1103. PubMed ID: 18519075
[No Abstract] [Full Text] [Related]
9. Comparison of topical 0.3% ofloxacin to fortified tobramycin-cefazolin in the therapy of bacterial keratitis.
Khokhar S; Sindhu N; Mirdha BR
Infection; 2000; 28(3):149-52. PubMed ID: 10879638
[TBL] [Abstract][Full Text] [Related]
10. Monotherapy versus fortified antibiotics for bacterial keratitis.
Rosenberg JB; Gritz DC
Cornea; 2011 Sep; 30(9):1066; author reply 1066-7. PubMed ID: 21775886
[No Abstract] [Full Text] [Related]
11. Fourth-generation fluoroquinolone-resistant bacterial keratitis.
Jhanji V; Sharma N; Satpathy G; Titiyal J
J Cataract Refract Surg; 2007 Aug; 33(8):1488-9. PubMed ID: 17662450
[TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolones in corneal ulcers.
Galvis V; Tello A; Guerra AR; Acuña MF; Villarreal D
Ophthalmology; 2013 Sep; 120(9):e61-2. PubMed ID: 24001539
[No Abstract] [Full Text] [Related]
13. Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).
Srinivasan M; Mascarenhas J; Rajaraman R; Ravindran M; Lalitha P; Glidden DV; Ray KJ; Hong KC; Oldenburg CE; Lee SM; Zegans ME; McLeod SD; Lietman TM; Acharya NR;
Arch Ophthalmol; 2012 Feb; 130(2):143-50. PubMed ID: 21987582
[TBL] [Abstract][Full Text] [Related]
14. The steroids for corneal ulcers trial: study design and baseline characteristics.
Srinivasan M; Mascarenhas J; Rajaraman R; Ravindran M; Lalitha P; Glidden DV; Ray KJ; Hong KC; Oldenburg CE; Lee SM; Zegans ME; McLeod SD; Lietman TM; Acharya NR;
Arch Ophthalmol; 2012 Feb; 130(2):151-7. PubMed ID: 21987581
[TBL] [Abstract][Full Text] [Related]
15. The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.
Srinivasan M; Mascarenhas J; Rajaraman R; Ravindran M; Lalitha P; O'Brien KS; Glidden DV; Ray KJ; Oldenburg CE; Zegans ME; Whitcher JP; McLeod SD; Porco TC; Lietman TM; Acharya NR;
Am J Ophthalmol; 2014 Feb; 157(2):327-333.e3. PubMed ID: 24315294
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
17. Gatifloxacin 0.3% Versus Fortified Tobramycin-Cefazolin in Treating Nonperforated Bacterial Corneal Ulcers: Randomized, Controlled Trial.
Bashir H; Dave A; Mathur U
Cornea; 2016 Aug; 35(8):e22-3. PubMed ID: 27227400
[No Abstract] [Full Text] [Related]
18. Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment.
Sy A; Srinivasan M; Mascarenhas J; Lalitha P; Rajaraman R; Ravindran M; Oldenburg CE; Ray KJ; Glidden D; Zegans ME; McLeod SD; Lietman TM; Acharya NR
Invest Ophthalmol Vis Sci; 2012 Jan; 53(1):267-72. PubMed ID: 22159005
[TBL] [Abstract][Full Text] [Related]
19. Nocardia keratitis: clinical course and effect of corticosteroids.
Lalitha P; Srinivasan M; Rajaraman R; Ravindran M; Mascarenhas J; Priya JL; Sy A; Oldenburg CE; Ray KJ; Zegans ME; McLeod SD; Lietman TM; Acharya NR
Am J Ophthalmol; 2012 Dec; 154(6):934-939.e1. PubMed ID: 22959881
[TBL] [Abstract][Full Text] [Related]
20. Author reply: To PMID 23415776.
Sharma N; Goel M; Bansal S; Agarwal P; Titiyal J; Upadhyaya A; Vajpayee R
Ophthalmology; 2013 Sep; 120(9):e62. PubMed ID: 24001541
[No Abstract] [Full Text] [Related]
[Next] [New Search]
